Stroke

Reperio Health Partners with Health Designs to Offer Employers At-Home Biometric Screening Tools

Retrieved on: 
Wednesday, April 6, 2022
Health, Medical Supplies, Other Health, Medical Devices, Risk, Cholesterol, Health, Heart, Population, Blood pressure, CDC, LDL, Adult, CEO, BMI, Workforce, Stroke, Diabetes, Degenerative disease, HDL, Solution, Conditional sentence, FDA, Partnership, Health insurance, Pharmaceutical industry

Reperio Health , a manufacturer of at-home health assessment screening tools that offer comprehensive, immediate and actionable results, today announced a new partnership with Health Designs , a provider of employer wellness programs designed to address workforces complete well-being needs.

Key Points: 
  • Reperio Health , a manufacturer of at-home health assessment screening tools that offer comprehensive, immediate and actionable results, today announced a new partnership with Health Designs , a provider of employer wellness programs designed to address workforces complete well-being needs.
  • The new partnership will provide Health Designs clientsa diverse group of employers in every major sector of the economywith access to Reperios convenient, at-home biometric screening solution that can be used anytime, anywhere.
  • Digital tools and solutions like Reperios will help employers across the country reach their entire workforce and meaningfully engage them in their well-being programs, says Christopher Margolin, CEO of Health Designs.
  • Founded in 1995, Health Designs pioneered many of the processes now considered the gold standard in the workplace wellness industry.

Jubilant Therapeutics Inc. reports isoform-selective PAD4 inhibitors demonstrating high In Vitro selectivity and potency and In Vivo oral bioavailability and anti-tumor activity

Retrieved on: 
Monday, April 11, 2022
Company, Cancer, Therapy, LinkedIn, Stroke, PRMT5, Degenerative disease, Thrombosis, Jubilant, Pre-eclampsia, Breast, AACR, Program, CDT, American Association, Metastasis, Chromatin, Citrulline, NETS, Poster, Inflammation, Association, Twitter, Pathway, Drug discovery, Neutrophil, Fibrosis, American Association for Cancer Research, Neutrophil extracellular traps, Algorithm, Pharmaceutical industry, Vaccine

The data reports on the pharmacokinetic and anti-cancer properties of isoform-selective peptidyl arginine deiminase 4 (PAD4) inhibitors as potential therapeutics to treat cancer.

Key Points: 
  • The data reports on the pharmacokinetic and anti-cancer properties of isoform-selective peptidyl arginine deiminase 4 (PAD4) inhibitors as potential therapeutics to treat cancer.
  • The first-in-class mechanism of PAD4 inhibition reduces neutrophil extra-cellular traps (NETs) which stimulates cancer cell adhesion, migration and invasion.
  • Jubilant Therapeutics Inc's drug discovery platform created a number of lead molecules with strong in vitro potency and high selectivity to PAD4 compared to PAD1, PAD2 or PAD3.
  • Jubilant Therapeutics Inc. is headquartered in Bedminster, NJ and guided by globally renowned key opinion leaders and scientific advisory board members.

Jubilant Therapeutics Inc. reports isoform-selective PAD4 inhibitors demonstrating high In Vitro selectivity and potency and In Vivo oral bioavailability and anti-tumor activity

Retrieved on: 
Monday, April 11, 2022
Company, Cancer, Therapy, LinkedIn, Stroke, PRMT5, Degenerative disease, Thrombosis, Jubilant, Pre-eclampsia, Breast, AACR, Program, CDT, American Association, Metastasis, Chromatin, Citrulline, NETS, Poster, Inflammation, Association, Twitter, Pathway, Drug discovery, Neutrophil, Fibrosis, American Association for Cancer Research, Neutrophil extracellular traps, Algorithm, Pharmaceutical industry, Vaccine

The data reports on the pharmacokinetic and anti-cancer properties of isoform-selective peptidyl arginine deiminase 4 (PAD4) inhibitors as potential therapeutics to treat cancer.

Key Points: 
  • The data reports on the pharmacokinetic and anti-cancer properties of isoform-selective peptidyl arginine deiminase 4 (PAD4) inhibitors as potential therapeutics to treat cancer.
  • The first-in-class mechanism of PAD4 inhibition reduces neutrophil extra-cellular traps (NETs) which stimulates cancer cell adhesion, migration and invasion.
  • Jubilant Therapeutics Inc's drug discovery platform created a number of lead molecules with strong in vitro potency and high selectivity to PAD4 compared to PAD1, PAD2 or PAD3.
  • Jubilant Therapeutics Inc. is headquartered in Bedminster, NJ and guided by globally renowned key opinion leaders and scientific advisory board members.

Semler to Participate in the 21st Annual Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, April 7, 2022
Risk, Conditional sentence, Infarction, Diagnosis, Conference, Food, Health, Technology, Food and Drug Administration, Stroke, Moyamoya disease, Nasdaq, Extremities, Solution, Efficiency, FDA, Insurance, Patient, Pharmaceutical industry

A live webcast will be available under "Events and Presentations" on the "Investor Info" section of the Semler Scientific website and may be accessed through the following link: https://wsw.com/webcast/needham117/smlr/2278090 .

Key Points: 
  • A live webcast will be available under "Events and Presentations" on the "Investor Info" section of the Semler Scientific website and may be accessed through the following link: https://wsw.com/webcast/needham117/smlr/2278090 .
  • The presentation will be archived for a period of 90 days after the conference.
  • Semler Scientific's mission is to develop, manufacture and market innovative products and services that assist its customers in evaluating and treating chronic diseases.
  • QuantaFlo is used by Semler Scientific's customers to more comprehensively evaluate their patients for risk of heart attacks and strokes.

Global Rehabilitation Robots Market Report 2022: Market to Reach $1.8 Billion by 2026 from $566.5 Million in 2020

Retrieved on: 
Wednesday, April 6, 2022
Rehabilitation robotics, CAGR, Survivor, Population, Lower, University, Growth, Rehabilitation, Hospital, Federation, Arthritis, Brain damage, Prevalence, Hand, Stroke, Ascending limb of loop of Henle, Ageing, Upper limb, Arm, Awareness, Disability, Patient, Orthotics, Pet, Health insurance, Human

DUBLIN, April 6, 2022 /PRNewswire/ -- The "Rehabilitation Robots - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 6, 2022 /PRNewswire/ -- The "Rehabilitation Robots - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Rehabilitation Robots estimated at US$566.5 Million in the year 2020, is projected to reach a revised size of US$1.8 Billion by 2026, growing at a CAGR of 21.7% over the analysis period.
  • The U.S. Market is Estimated at $253.1 Million in 2021, While China is Forecast to Reach $268.7 Million by 2026
    The Rehabilitation Robots market in the U.S. is estimated at US$253.1 Million in the year 2021.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$45.9 Million by the year 2026.

Geisinger's MyCode Community Health Initiative hits milestone, enrolls 300,000 participants

Retrieved on: 
Wednesday, April 6, 2022
Geisinger, Risk, Cancer, Genomic Medicine Institute, FH, List of counseling topics, LinkedIn, Obesity, BRCA1, Bipolar disorder, DNA, Infarction, Hereditary nonpolyposis colorectal cancer, Diagnosis, Growth, Genetics, Breast, Benaroya Research Institute, GSC, Program, Geisinger Commonwealth School of Medicine, Genomics, Health, BRCA2, Cardiomyopathy, Autism, Schizophrenia, Learning, Stroke, Twitter, Epilepsy, Gene, Degenerative disease, Physician, Hereditary breast–ovarian cancer syndrome, Lists of diseases, Instagram, Patient, Disease, Health insurance, Pharmaceutical industry, Facebook

DANVILLE, Pa., April 6, 2022 /PRNewswire/ -- Geisinger's precision health project, MyCode, has enrolled 300,000 participants, reaching a major milestone for the program. With DNA sequence and health data currently available on nearly 185,000 of these participants, MyCode is the largest healthcare system-based study of its kind.

Key Points: 
  • DANVILLE, Pa., April 6, 2022 /PRNewswire/ --Geisinger's precision health project, MyCode , has enrolled 300,000 participants, reaching a major milestone for the program.
  • With DNA sequence and health data currently available on nearly 185,000 of these participants, MyCode is the largest healthcare system-based study of its kind.
  • The MyCode Community Health Initiative was one of the first programs to return clinically actionable results to patient-participants through its Genomic Screening and Counseling (GSC) Program, pioneered by Amy Sturm, M.S., and Adam Buchanan, M.S., M.P.H., of Geisinger's Genomic Medicine Institute.
  • Analysis of MyCode data has contributed to a number of groundbreaking discoveries, including a rare genetic variant that protects against obesity .

Englewood Health Named a Top Hospital in New Jersey

Retrieved on: 
Wednesday, April 6, 2022
Magnet, Hackensack Meridian Health, Běštín, Anesthesiology, Partnership, Englewood Hospital and Medical Center, Emergency medicine, Lists of diseases, Best, Pathology, Hospital, CEO, Health, Pain management, Communication, Magnet Recognition Program, Stroke, Prostate cancer, Knee, Hackensack Meridian School of Medicine, Heart, Englewood, Breast cancer, Patient, Medicine

ENGLEWOOD, N.J., April 6, 2022 /PRNewswire/ -- Englewood Health has been named a top hospital in New Jersey by Jersey's Best magazine.

Key Points: 
  • ENGLEWOOD, N.J., April 6, 2022 /PRNewswire/ -- Englewood Health has been named a top hospital in New Jersey by Jersey's Best magazine.
  • Englewood Health was named a top hospital overall, as well as a top hospital for the treatment of high-risk pregnancy and childbirth; prostate cancer; breast cancer; knee and hip replacement; stroke; congestive heart failure; neurological disorders; coronary artery bypass surgery; and pain management.
  • "We are honored to be recognized as one of the top hospitals in New Jersey," said Warren Geller, president and CEO of Englewood Health.
  • Composed of Englewood Hospital, the Englewood Health Physician Network, and the Englewood Health Foundation, the health system delivers nationally recognized care in a community setting to residents of northern New Jersey, New York, and beyond.

American Academy of Neurology Launches New Brain & Life Podcast

Retrieved on: 
Wednesday, April 6, 2022
Brain, Human, LinkedIn, Multiple sclerosis, American Academy of Neurology, Life, Caregiver, Migraine, Association, FAAN, Doctor of Philosophy, Parkinson's disease, Nervous system, Concussion, Stroke, Twitter, Person, Master of Science, Lists of diseases, Epilepsy, American Academy, Academy, AAN, YouTube, Instagram, Accessory nerve disorder, Alzheimer's disease, Patient, Pharmaceutical industry, Medical imaging, Mobile phone, MD, Facebook, Neurology

MINNEAPOLIS, April 6, 2022 /PRNewswire/ -- The American Academy of Neurology announced the launch of its latest podcast, Brain & Life. The weekly podcast will explore the intersection of brain health and neurologic disease. Each week neurologist co-hosts Daniel J. Correa, MD, MSc, FAAN, and Audrey R. Nath, MD, PhD, will engage in lively conversations with neurology experts, celebrity advocates, and people whose lives are affected by neurologic conditions including actor and comedian George Lopez, comedian Josh Blue, actress Marilu Henner and more.

Key Points: 
  • MINNEAPOLIS, April 6, 2022 /PRNewswire/ --The American Academy of Neurology announced the launch of its latest podcast, Brain & Life.
  • Inspired by the Academy's highly successful Brain & Life magazine for patients and caregivers,Brain & Life is the only podcast dedicated to exploring the connections between brain health and neurologic conditions while elevating the voices of those in the neurology community.
  • We will tackle those questions and more in the Brain & Life podcast," said Correa.
  • For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook , Twitter , Instagram , LinkedIn and YouTube .

UPNEEQ® Wins "Best in Innovation" Award from New Beauty

Retrieved on: 
Wednesday, April 6, 2022
Duane syndrome, Company, Ophthalmoparesis, Orthostatic hypotension, Risk, Blepharoplasty, Metabolism, Headache, Blood pressure, U.S. FDA, EVP, Myasthenia gravis, Glaucoma, Glycosidic bond, Patient, Aneurysm, Focal neurologic signs, Cardiovascular disease, Hypertension, Industry, Stroke, Oxymetazoline, Beta blocker, Nasdaq, Ptosis, Mark (given name), Horner's syndrome, Xanthine oxidase inhibitor, Orbit, Hypotension, FDA, Education, Eye, Eye injury, Pharmaceutical industry, Phosphorus, Leptodeira

BRIDGEWATER, N.J. , April 6, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (Nasdaq: RVLP) announced today that its U.S. FDA approved acquired blepharoptosis (ptosis) drug UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of a "Best  in Innovation" award in the 12th Annual Beauty Awards conducted by New Beauty, a Sandow Publication.

Key Points: 
  • New Beauty, a trend-driven education-powered quarterly published resource and website, has been a leader in the aesthetic space since its launch in 2005.
  • New Beauty Features Editor, Tatiana Bido, said of the non-surgical option to treat adults with acquired ptosis, "UPNEEQ is an instant eye-lifter for adults with acquired ptosis or low-lying eyelids.
  • "We are thrilled to be acknowledged by New Beauty with an Innovation Award for UPNEEQ," said JD Schaub, EVP & Chief Operating Officer.
  • Industry support and validation like this award from New Beauty is further proof of concept."

MXR Imaging Announces Distribution Agreement With Micro-X

Retrieved on: 
Wednesday, April 6, 2022
Company, Medical Research Future Fund, Diagnosis, Rover, National, Global health, Improvised explosive device, Health, ASX, Technology, Stroke, MXR, Google Images, Australian government debt, Ambulance, SAN, RSNA, CNT, Television, Medical imaging, Micro-X-ray fluorescence, Micro-X-ray fluorescence

SAN DIEGO, April 6, 2022 /PRNewswire/ -- MXR Imaging, Inc. is pleased to announce the signing of a non-exclusive distribution agreement in the United States with Micro-X, the leader in cold cathode x-ray technology for health and security markets globally.

Key Points: 
  • MXR is pleased to announce the signing of a non-exclusive distribution agreement in the United States with Micro-X.
  • SAN DIEGO, April 6, 2022 /PRNewswire/ -- MXR Imaging, Inc. is pleased to announce the signing of a non-exclusive distribution agreement in the United States with Micro-X, the leader in cold cathode x-ray technology for health and security markets globally.
  • MXR Imaging signs multi-year distribution agreement of the Rover in the U.S.
    MXR Imaging is the largest independent distributor of imaging sales and service in the U.S.
  • MXR Imaging has received strong interest in the products from our customer base, especially following Micro-X's successful debut at the RSNA conference in late 2021.